key: cord-0892734-z844tuii
authors: Falcoz, Pierre-Emmanuel; Monnier, Alexandra; Puyraveau, Marc; Perrier, Stephanie; Ludes, Pierre-Olivier; Olland, Anne; Mertes, Paul-Michel; Schneider, Francis; Helms, Julie
title: Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19–related Acute Respiratory Distress Syndrome: Worth the Effort?
date: 2020-08-01
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202004-1370le
sha: 20daccfbd1ea98f0c6a8ba3a72368b7080454921
doc_id: 892734
cord_uid: z844tuii

nan

To the Editor:

According to Chinese and Italian reports, 15-42% of patients with coronavirus disease (COVID-19) develop acute respiratory distress syndrome (ARDS), with a 60% mortality rate (1) (2) (3) . Venovenous extracorporeal membrane oxygenation (VV-ECMO) is therefore considered a rescue therapy to be used in the most severe ARDS, as recommended by the World Health Organization's interim guidelines for the management of patients with COVID-19 (4). However, without a significant impact on mortality, the benefit of ECMO in ARDS remains controversial (5) . Generally, only few data on the use of ECMO in the present pandemic are available (1, 2) with a short follow-up (6, 7) . However, accurately selecting patients with COVID-19-related ARDS, who may be good candidates for ECMO support, is important during a pandemic characterized by limited medical resources.

We prospectively included all patients referred to the five ICUs of the Strasbourg University Hospital, between March 3 and April 1, 2020, for severe ARDS due to COVID-19 (confirmed by RT-PCR test), and that had been supported by ECMO after failure of optimal medical treatment, including neuromuscular blocking agents, protective ventilation, and high positive end-expiratory pressure (PEEP). According to EOLIA (ECMO to Rescue Lung Injury in Severe ARDS) criteria (5), patients were eligible for ECMO if they developed a refractory ARDS defined by a Pa O 2 /FI O 2 , 80 mm Hg or a pH , 7.25 with a Pa CO2 . 60 mm Hg for more than 6 hours with a FI O 2 . 80%, despite low-pressure ventilation strategies and no participation of fluid overload. The contraindications for ECMO implantation were an age older than 70 years and severe comorbidities, including severe chronic respiratory failure, severe cardiac failure, and Child Pugh C cirrhosis. Invasive mechanical ventilation for more than 7 days was a relative contraindication.

This study was approved by the institutional ethics committee of the Strasbourg University Hospital (ClinicalTrials ID: NCT04343404). Informed consent was waived as part of a public health outbreak investigation. SAS version 9.4 (SAS Institute) was used for all statistical analyses. Continuous variables are presented as median and ranges and were compared using nonparametric signed rank tests.

Seventeen patients (4.5% of all those with ARDS admitted to our hospital's ICUs during the study period, n = 377) were supported by ECMO. The clinical presentation, ICU therapies, and outcomes are shown in Table 1 . At the time of ECMO implantation, median Pa O 2 /FI O 2 was 71 (52-134) mm Hg and Sequential Organ Failure Assessment score was 8 (3-15). Sixteen patients had been prone positioned before ECMO implantation.

Sixteen patients were supported with VV-ECMO (12 Avalon cannula and 4 jugulofemoral cannulations). One was supported with venoarterial femorofemoral ECMO because of respiratory failure complicated by cardiogenic shock due to pulmonary embolism. All patients were eligible for ECMO because of a Pa O 2 /FI O 2 , 80 mm Hg (n = 16) or blood pH of ,7.25 with a Pa CO2 of at least 60 mm Hg for more than 6 hours (n = 1). The median blood flow was 4 (0-6) L/min. In accordance with the French Society of Hematology's recommendations for patients with COVID-19, all patients were treated with therapeutic dosing of unfractioned heparin (anti-Xa 0.5-0.7 UI/ml) (8) .

After ECMO implantation, the median VT was significantly decreased from 5.9 to 3.9 ml/kg (P , 0.01) and PEEP from 14 to 12 cm of water (P , 0.02) with a lower plateau pressure: Under ECMO, six patients had bleeding complications requiring transfusion. Most of the complications (in 5/6 patients, 83.3%) were due to bleeding at site of cannula insertion, and one was the result of a gastrointestinal bleeding. Despite therapeutic dosing of unfractioned heparin, we observed three oxygenator thromboses in two patients, and four patients developed thrombotic or ischemic complications under ECMO (Table 1) .

At day 60, six patients (35.3%) had died and only one (5.9%) patient was still in the ICU receiving mechanical ventilation. All 10 (58.8%) patients discharged from the ICU were weaned from mechanical ventilation, and among them, 7 (41.1%) patients were discharged from the hospital (Figure 1 ).

VV-ECMO facilitated protective ventilation with decreased plateau pressure, respiratory rate, and VT in patients with COVID-19 with refractory ARDS. Compared with the EOLIA study, only a single patient was cannulated for indication related to pressure and the ECMO duration was shorter overall, which might be linked to the specificity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced lung damages (9) . To date, according to our usual strategy, no more prone positioning procedure was realized under ECMO, the pandemic-induced work overload being also a limitation.

ECMO support is associated with an increased risk of both thrombotic and hemorrhagic complications. Considering the high risk of thrombotic complications in patients with severe COVID-19, we chose higher anticoagulation targets for all of our patients than usual, even if most of them were under VV-ECMO. Indeed, a high proportion of patients with COVID-19 developed life-threatening thrombotic complications. In an autopsy series (9) , most of the patients were diagnosed with deep vein thrombosis or pulmonary embolisms. Furthermore, we have recently demonstrated that despite anticoagulation, patients with ARDS related to COVID-19 developed more thrombotic complications, secondary to the major systemic inflammatory response along with endothelial dysfunction (10) . Furthermore, although 35.3% of the patients required blood transfusion, only one (5.8%) has developed hemorrhagic shock. Considering the high risk of thrombotic events in patients with COVID-19, we suggest that a therapeutic anticoagulation may be considered. Otherwise, despite higher targets of anticoagulation, we failed to prevent oxygenator thrombosis, requiring an urgent switch of the circuit. Indeed, only 7% of the circuits were changed in the EOLIA study because of clotting, compared with 12% in our cohort. Thus, the thrombotic complications seem to be more life-threatening than the hemorrhagic ones.

Considering the high frequency of severe adverse events, ECMO should probably remain a rescue therapy and therefore be undertaken only in ECMO-expert centers with adequate resources. In our cohort, one patient did indeed die during cannulation secondary to a cardiac tamponade.

The main strength of our study is to prospectively describe the clinical course of patients with COVID-19 who required ECMO, particularly as only few data are available. Our results are however limited by their single-center character.

In conclusion, although VV-ECMO is burdened with a high rate of life-threatening complications, it might be considered as a After 60 days of follow-up, six patients (35.3%) had died. All survivors except one had been weaned from mechanical ventilation and discharged from the ICU. Three (17.6%) patients were still hospitalized, and seven patients were discharged from the hospital (*). ECMO = extracorporeal membrane oxygenation.

Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

Detection of SARS-CoV-2 in different types of clinical specimens

Q&A: the novel coronavirus outbreak causing COVID-19

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region

Clinical course and outcomes of 344 intensive care patients with COVID-19

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients

The role of extracorporeal life support for patients with COVID-19: preliminary results from a statewide experience

Traitement anticoagulant pour la prévention du risque thrombotique chez le patient hospitalisé avec le COVID-19 et surveillance de l'hémostase

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis)

Fluid Resuscitation, and Hypoxemia in Malawian Patients with Suspected Sepsis To the Editor: The optimal approach to fluid resuscitation for patients with sepsis is uncertain. Data from sub-Saharan Africa have

ARCS" was commissioned by the UK National Institute of Health Research using Official Development Assistance funding. No funders had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this publication are those of the authors and not necessarily those of the

Data analysis: R.J.W. First draft of manuscript: R.J.W. Critical revision of the manuscript for important intellectual content